Group 1 - Venu Holding Corporation conducted its initial public offering on November 27, 2024, issuing 1.2 million shares at a price of $10.00 per share [1] - On November 14, 2025, Venu reported third-quarter financial results, revealing revenue of $5.38 million, which was a 1.3% year-over-year decline and missed consensus estimates by $2.05 million [1] - Following the financial report, Venu's share price dropped by $2.37, or approximately 21.45%, from $11.05 on November 14, 2025, to close at $8.68 on November 17, 2025 [1] Group 2 - Kirby McInerney LLP is investigating potential violations of federal securities laws by Venu and its senior management [1] - No lawsuit has been filed yet, and the investigation aims to determine if claims can be brought under federal securities laws [2] - The law firm specializes in securities litigation and has achieved recoveries totaling billions of dollars for shareholders [3]

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. for allegedly misleading investors regarding its accounts receivable practices during the Class Period from July 18, 2024, to November 12, 2025 [4]. Group 1: Lawsuit Details - The lawsuit claims that Ardent misrepresented its method of determining the collectability of accounts receivable, stating it used detailed historical reviews, while in reality, it relied on a 180-day cliff for reserving accounts [4]. - On November 12, 2025, Ardent disclosed a $43 million reduction in revenue and a $54 million increase in professional liability reserves, leading to a significant drop in share price by approximately 33.8% [5]. Group 2: Investor Actions - Investors have until March 9, 2026, to apply to be appointed as lead plaintiff in the class action, which allows them to oversee litigation and influence key decisions [2]. - The law firm Kirby McInerney LLP is handling the case and encourages affected investors to contact them for more information [7].

Core Viewpoint - Fermi Inc. is facing a class action lawsuit due to allegations of securities fraud related to its Project Matador campus, with significant implications for investors who purchased shares during the specified class period [3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Fermi securities between September 28, 2025, and December 11, 2025, alleging that the company overstated tenant demand for its Project Matador campus [3]. - Allegations include the reliance on a single tenant's funding commitment for financing the construction of Project Matador and the risk of that tenant terminating its funding commitment [3]. - Fermi's share price dropped significantly after the announcement that the first tenant had terminated a $150 million funding agreement, leading to a decline of approximately 33.8% from $15.25 to $10.09 per share [4]. Group 2: Investor Actions - Investors who suffered losses on their Fermi investments have until March 6, 2026, to request lead plaintiff appointment, which is crucial for overseeing the litigation [2]. - Individual investors can be appointed as lead plaintiffs, influencing key decisions in the lawsuit [2]. - Interested parties are encouraged to contact Kirby McInerney LLP for more information regarding their rights and interests in the lawsuit [5].

Core Viewpoint - The law firm Kirby McInerney LLP is investigating Soleno Therapeutics, Inc. for potential violations of federal securities laws or unlawful business practices related to its product Vykat XR [1]. Group 1: Company Performance and Events - On August 15, 2025, Scorpion Capital published a report labeling Soleno's Vykat XR as overpriced and potentially unsafe for children, leading to a share price decline of $5.73, or approximately 7.41%, from $77.36 to $71.64 [3]. - During a quarterly earnings call on November 4, 2025, Soleno disclosed that the discontinuation rate of Vykat XR due to adverse effects was around 8% at the end of Q3 2025. The CEO noted a disruption in the product's launch trajectory following the Scorpion Capital report, resulting in a further share price drop of $16.98, or approximately 26.59%, from $63.85 to $46.87 [4].

Core Points - A class action lawsuit has been filed against Coreweave, Inc. for alleged misstatements regarding its ability to meet customer demand and the risks associated with reliance on a single third-party data center supplier [2][6] - Investors who suffered losses during the class period from March 28, 2025, to December 15, 2025, can request lead plaintiff appointment until March 13, 2026 [1][6] Financial Impact - On October 30, 2025, Coreweave's shares fell by approximately 5.5%, from $133.71 to $126.32, following the announcement of the termination of its merger agreement with Core Scientific due to insufficient shareholder votes [3] - Following a press release on November 10, 2025, regarding lowered guidance due to delays from a third-party data center, Coreweave's shares dropped by about 16.3%, from $105.61 to $88.39 [4] - An article published on December 15, 2025, highlighted further delays in the completion of a significant data center project, leading to a decline of approximately 7.9% in share price, from $78.59 to $72.35 [5] Company Statements - Coreweave maintains that its strategy remains unchanged despite the challenges faced, emphasizing a commitment to long-term shareholder value through strategic mergers and acquisitions [3] - Co-founder Michael Intrator initially stated that the quarter's performance was as planned, except for delays at a singular data center, later clarifying the issue pertained to a singular data center provider [4]

Core Viewpoint - Venu Holding Corporation is under investigation for potential violations of federal securities laws or unlawful business practices by its senior management [1]. Group 1: Company Overview - Venu conducted its initial public offering on November 27, 2024, offering 1.2 million shares at a price of $10.00 per share [3]. - The company reported third-quarter financial results on November 14, 2025, with revenue of $5.38 million, which is a 1.3% decline year-over-year and fell short of consensus estimates by $2.05 million [3]. Group 2: Market Reaction - Following the financial results announcement, Venu's share price dropped by $2.37, approximately 21.45%, from $11.05 on November 14, 2025, to close at $8.68 on November 17, 2025 [3].

Core Viewpoint - Soleno Therapeutics, Inc. is under investigation for potential violations of federal securities laws following negative reports about its product Vykat XR, which has led to significant declines in its stock price [1][2]. Group 1: Company Performance - On August 15, 2025, a report by Scorpion Capital labeled Vykat XR as overpriced and potentially unsafe for children, resulting in a stock price drop of $5.73, or approximately 7.41%, from $77.36 to $71.64 [1]. - During the quarterly earnings call on November 4, 2025, Soleno disclosed a discontinuation rate of approximately 8% for Vykat XR due to adverse effects, which contributed to a further decline in stock price by $16.98, or approximately 26.59%, from $63.85 to $46.87 [2]. Group 2: Management Response - The CEO of Soleno acknowledged a disruption in the launch trajectory of Vykat XR following the negative report from Scorpion Capital, citing a decrease in start forms and an increase in discontinuations for non-serious adverse events [2].

Group 1 - The law firm Kirby McInerney LLP is investigating Paysafe Limited for possible violations of federal securities laws or other unlawful business practices [1] - On November 13, 2025, Paysafe reported its Q3 2025 financial results, missing revenue and EPS estimates due to a last-minute client shutdown that resulted in a several-million-dollar write-down [2] - Following the announcement, Paysafe's share price fell by $2.80, approximately 27.6%, from $10.16 on November 12, 2025, to close at $7.36 on November 13, 2025 [2] Group 2 - Investors who purchased or acquired Paysafe securities and have information regarding the investigation are encouraged to contact Kirby McInerney LLP for further discussion [3] - Kirby McInerney LLP specializes in securities, antitrust, whistleblower, and consumer litigation, with a history of achieving recoveries totaling billions of dollars for shareholders [4]

Core Viewpoint - The article discusses a pending federal securities class action against Klarna Group plc, highlighting the deadline for investors to seek the role of lead plaintiff and the allegations regarding misleading statements in the company's IPO registration statement [1][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Klarna securities between September 7, 2025, and December 22, 2025, alleging that the IPO registration statement contained false or misleading statements [4]. - It is claimed that Klarna materially understated the risk of increased loss reserves shortly after its IPO, which was known or should have been known given the risk profile of its customers [4]. Group 2: IPO and Financial Performance - Klarna launched its IPO in September 2025, selling 34,311,274 shares at a price of $40.00 per share [5]. - Following the announcement of disappointing Q3 2025 financial results on November 18, 2025, which included a significant increase in credit loss provisions, Klarna's share price fell by $3.25, or approximately 9.3%, from $34.88 to $31.63 [5].

Core Viewpoint - Kirby McInerney LLP is investigating Soleno Therapeutics, Inc. for potential violations of federal securities laws or unlawful business practices related to its product Vykat XR [1] Group 1: Company Performance and Events - On August 15, 2025, Scorpion Capital published a report labeling Vykat XR as overpriced and potentially unsafe for children, leading to a decline in Soleno's share price by $5.73, or approximately 7.41%, from $77.36 to $71.64 [3] - During the quarterly earnings call on November 4, 2025, Soleno disclosed a discontinuation rate of approximately 8% for Vykat XR due to adverse effects, which contributed to a further decline in share price by $16.98, or approximately 26.59%, from $63.85 to $46.87 [4]